Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q3 FY25 results · Oct–Dec 2024
Onesource Specialty Pharma reported revenue from operations of ₹392.56 crore and net loss of ₹68.85 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 392.56 | — | — | 67.98 | +477.5% |
| Other income | 5.39 | — | — | 0.58 | +826.6% |
| Total income | 397.96 | — | — | 68.56 | +480.4% |
| Profit before tax | (66.50) | — | — | (39.08) | Loss widened |
| Net profit for the period | (68.85) | — | — | (39.33) | Loss widened |
| EPS, basic (₹) | (6.31) | — | — | (18.82) | not comparable |
| Net margin (%) | -17.5 | — | -57.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 336.75 | — | — | 67.98 | +395.4% |
| Other income | 5.01 | — | — | 0.58 | +758.7% |
| Total income | 341.76 | — | — | 68.56 | +398.5% |
| Profit before tax | (73.02) | — | — | (40.02) | Loss widened |
| Net profit for the period | (73.02) | — | — | (40.02) | Loss widened |
| EPS, basic (₹) | (6.69) | — | — | (19.26) | not comparable |
| Net margin (%) | -21.7 | — | -58.9 |
Consolidated
- Filed with BSE
- 29 Jan 2025, 18:40 IST
- Board meeting
- 29 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2025, 18:40 IST
- Board meeting
- 29 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE